Better news cheers mood at Spectrum Pharmaceuticals

29 July 2020

At the end of 2019, the failure of a key Phase II test of poziotinib hollowed out shares in Nevada, USA-based oncology firm Spectrum Pharmaceuticals (Nasdaq: SPPI).

In a surprise turnaround, an analysis of the second cohort of the same trial provided a positive result, the firm announced on Monday, lifting shares by as much as 50%.

Spectrum is testing the oral EGF tyrosine kinase inhibitor (EGFR TKI) in the ZENITH20 trial, as an option for people with pre-treated non-small cell lung cancer (NSCLC) with exon 20 insertions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK